Ametumumab

安美木单抗

Report date: 2023/01/16 13:41:38

Base Information

Drug NameAmetumumab
Drug Alias Name重组全人源抗EGFR单抗注射液（赛伦生物）Recombinant fully human anti-EGFR mAb (Shanghai Serum Biotechnology)重组全人源抗EGFR单克隆抗体注射液（赛伦生物）Recombinant human anti-EGFR mAb (Serum Biotechnology)SY-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInstitute of Bioengineering Academy of Military Medical Sciences Chinese People's Liberation ArmyShanghai Serum Bio-Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Saiyuan Biotechnology Co LtdShanghai Celfuture Biotech Co LtdInstitute of Bioengineering Academy of Military Medical Sciences Chinese People's Liberation Army +[4] 
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A